This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mayr, L. M. Articles by Fuerst, P. Search for Related Content PubMed PubMed Citation Articles by Mayr, L. M. Articles by Fuerst, P. Social Bookmarking                         What's this?

The Future of High-Throughput Screening

Novartis Institutes of BioMedical Research, Center of Proteomic Chemistry, Basel, Switzerland, Lorenz.Mayr{at}novartis.com

Peter Fuerst

Novartis Institutes of BioMedical Research, Center of Proteomic Chemistry, Basel, Switzerland

High-throughput screening (HTS) is a well-established process in lead discovery for pharma and biotech companies and is now also being set up for basic and applied research in academia and some research hospitals. Since its first advent in the early to mid-1990s, the field of HTS has seen not only a continuous change in technology and processes but also an adaptation to various needs in lead discovery. HTS has now evolved into a quite mature discipline of modern drug discovery. Whereas in previous years, much emphasis has been put toward a steady increase in capacity ("quantitative increase") via various strategies in the fields of automation and miniaturization, the past years have seen a steady shift toward higher content and quality ("quality increase") for these biological test systems. Today, many experts in the field see HTS at the crossroads with the need to decide either toward further increase in throughput or more focus toward relevance of biological data. In this article, the authors describe the development of HTS over the past decade and point out their own ideas for future directions of HTS in biomedical research. They predict that the trend toward further miniaturization will slow down with the implementation of 384-well, 1536-well, and 384 low-volume-well plates. The authors predict that, ultimately, each hit-finding strategy will be much more project related, tailor-made, and better integrated into the broader drug discovery efforts. (Journal of Biomolecular Screening 2008:443-448)

Key Words: high-throughput screening • lead finding • drug discovery • miniaturization • automation

Journal of Biomolecular Screening, Vol. 13, No. 6, 443-448 (2008)
DOI: 10.1177/1087057108319644


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. P. Janzen and I. G. Popa-Burke Review: Advances in Improving the Quality and Flexibility of Compound Management J Biomol Screen, June 1, 2009; 14(5): 444 - 451. [Abstract] [PDF]

				M. J. Pfeifer and G. Scheel Long-Term Storage of Compound Solutions for High-Throughput Screening by Using a Novel 1536-Well Microplate J Biomol Screen, June 1, 2009; 14(5): 492 - 498. [Abstract] [PDF]

				M. Zaragoza-Sundqvist, H. Eriksson, M. Rohman, and P. J. Greasley High-Quality Cost-Effective Compound Management Support for HTS J Biomol Screen, June 1, 2009; 14(5): 509 - 514. [Abstract] [PDF]